Boston, Mass. — Revere Pharmaceuticals, an emerging biopharmaceutical company developing small molecule drugs targeting the Ras-homologous (Rho) family GTPases, announced the completion of an exclusive option and license agreement with Fosun USA to develop and commercialize products targeting Rac1 and Cdc42 in China.
Under the terms of the agreement, the license grants Fosun rights to an initial product to be specified and an option to an additional product for any indication targeting either Rac1 or Cdc42. Revere retains all rights in the rest of the world (outside China). Revere received an upfront payment and is eligible for preclinical and clinical milestones, commercial milestones and tiered royalties on net sales in the China territory.
“We are pleased to announce this important strategic partnership with Fosun Pharma” said Bob Silverman, Chief Executive Officer of Revere. “Our deal with Fosun represents an important catalyst for Revere, and we are now well-positioned to bring forth first-in-class inhibitors of Rho GTPases to address areas of high, unmet need.”
About Rho GTPases
Rho GTPases are a diverse group of signaling proteins, including Rac1 and CDC42 characterized by their ability to bind to the guanosine triphosphate (GTP) nucleotide and hydrolyze it to guanosine diphosphate (GDP). Activity of these proteins switch between the inactive GDP-bound form and the active GTP-bound form which recruits other downstream effector proteins to promote many critical cancer processes, including cell growth, migration, invasion, and angiogenesis. Dysregulation of Rac1 or Cdc42 is implicated in multiple cancer types including lung, breast, prostate, colorectal, and gastric cancer and is commonly associated with resistance to chemotherapy and other targeted cancer therapeutics. Rho GTPase dysregulation has also been implicated in chronic kidney disease and viral infections such as SARS CoV2.
About Fosun Pharma USA
Fosun Pharma USA Inc. established in 2017, is a subsidiary of a leading global healthcare group, Fosun Pharma and Fosun International. Based in Princeton, New Jersey, Fosun Pharma USA markets specialty injectables, develops partnerships to bring late-stage assets to the U.S. and China markets, and seeks investment opportunities with cutting-edge healthcare technologies through FUSION, our drug discovery incubator. For more information, please visit www. https://fosunpharmausa.com.
About Revere Pharmaceuticals
Revere Pharmaceuticals is a biopharmaceutical company developing small molecule drugs targeting the Ras-homologous (Rho) family GTPases, molecular switches that are central to cancer progression and other disease processes. Based on a deep understanding of how to balance the active and inactive forms of the GTPase, the company has built a pipeline of novel small molecules that target Rac1, select Rac1 variants and CDC42. The company is headquartered in Boston, Massachusetts. For more information, please visit www.reverepharma.com.